S troke is a leading cause of longterm disability in the United States, affecting an estimated 6.4 million Americans. 1 Long-term disability is often associated with persistent impairment of an upper limb. 2 Despite the development of many programs for recovery after stroke, the effectiveness of rehabilitation in improving functioning and quality of life for patients with deficits more than 6 months after a stroke has not been definitively shown. Robotic rehabilitation devices have the potential to deliver highintensity, reproducible therapy. Advances in robotics and an increased understanding of the latent neurologic potential for stroke recovery led to our initiation of this multicenter, randomized, controlled trial, called the Veterans Affairs (VA) Robotic-Assisted Upper-Limb Neurorehabilitation in Stroke Patients study, to determine whether a rehabilitation protocol using the MIT-Manus robotic system (Interactive Motion Technologies), 3 as compared with a program based on conventional rehabilitative techniques or usual care, could improve functioning and quality of life of stroke survivors with long-term upper-limb deficits.
Me thods

Study Design
Details regarding the study design and baseline characteristics of the patients have been reported previously. 4 The study was approved by the institutional review board at each medical center and by the human rights committee at the coordinating center. An independent data and safety monitoring board oversaw the conduct, safety, and efficacy of the trial. Sponsorship and oversight were provided by the Veterans Affairs (VA) Cooperative Studies Program, with additional funding from the VA Rehabilitation Research and Development Service. The sponsors reviewed the manuscript before publication but were not responsible for the interpretation of the results or the decision to submit the manuscript for publication. The planning committee designed the trial, the participating investigators collected the data, and the listed authors wrote the manuscript. Study biostatisticians at the coordinating center had full access to the data and vouch for the accuracy and completeness of the analyses. The robotic system and all other rehabilitative equipment were purchased by the Department of Veterans Affairs through the VA Cooperative Studies Program Pharmacy Coordinating Center in Albuquerque, New Mexico. The robot manufacturer had no role in the study.
Study Population
We recruited veterans from four participating VA medical centers who were 18 years of age or older and had long-term, moderate-to-severe motor impairment of an upper limb from a stroke that had occurred at least 6 months before enrollment. Such impairment was defined as a score of 7 to 38 on the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke, 5 a scale with scores for upper-limb impairment ranging from 0 (no function) to 66 (normal function). All patients provided written informed consent.
Study Interventions
Patients were randomly assigned to receive robotassisted therapy, intensive comparison therapy, or usual care with the use of a permuted-block design that was stratified according to site. Robotassisted therapy was administered for a maximum of 36 sessions over a period of 12 weeks (up to 14 weeks to allow for missed sessions).
The robotic system consisted of four modules: a shoulder-elbow unit for horizontal movements; an antigravity unit for vertical movements; a wrist unit for flexion-extension, abduction-adduction, and pronation-supination movements; and a grasphand unit for closing and opening movements. The 12 weeks of training consisted of four training blocks and were supervised by a therapist. In the first 3-week block, a planar shoulder-andelbow training robotic device was used. In the second 3-week block, an antigravity shoulder and grasp-hand device was used. In the third 3-week block, the wrist robot was used. In the final block, all three devices were used to integrate proximal (shoulder) to distal (wrist and hand) training (see video).
Modules were used separately and in combination to perform high-intensity, repetitive, taskoriented movements (1024 per session on average), directed by video screens. Training targeted isolated proximal, distal, and integrated movements of the upper limb. The robot provided assistance if patients were unable to initiate or complete a movement independently.
Intensive comparison therapy consisted of a structured protocol using conventional rehabilitative techniques, such as assisted stretching, shoulder-stabilization activities, arm exercises, and functional reaching tasks. This therapy matched robot-assisted therapy in schedule and in the form and intensity of movements. 4, 6 The same research personnel delivered both robot-assisted therapy and intensive comparison therapy at each site.
The usual-care group received customary care available to all patients (i.e., medical management, clinic visits as needed, and in some cases rehabilitation services), which was not dictated by the protocol. Patients in the usual-care group were offered their choice of robot-assisted therapy or intensive comparison therapy after their final study visit.
Outcome Measures
Trained evaluators who were unaware of studygroup assignments assessed patients 6, 12, 24, and 36 weeks after randomization. The primary outcome was a change in the Fugl-Meyer score at 12 weeks, as compared with the baseline value. Secondary outcomes were changes in the score on the Wolf Motor Function Test 7, 8 and in the score on the Stroke Impact Scale, version 3.0, at 12 weeks, as compared with baseline values. 9 The Wolf Motor Function Test measures proximal and distal upper-limb motor control and consists of two strength measurements and 15 timed functional tasks. The tasks are averaged to produce a score in seconds that ranges from 0 to 120 seconds, with higher scores indicating worse functioning. The Stroke Impact Scale evaluates function and quality of life in eight clinically relevant domains on the basis of self-report. The domains of hand function, activities of daily living, instrumental activities of daily living, mobility, and social participation were used; scores range from 0 to 100, with higher values indicating better functioning and social participation.
Safety outcomes included the occurrence of adverse events and measures of pain (rated on a scale of 0 to 10, with higher scores indicating more severe pain) and spasticity (rated on the Modified Ashworth Scale, 10 which ranges from 0 to 5, with higher scores indicating more severe spasticity). Site personnel inquired about adverse and serious adverse events at each study contact. Patients did not keep lists or diaries of adverse events.
Cost Analysis
We used the purchase price of each robot (assuming full depreciation over a period of 5 years) to estimate the cost per session of robot-assisted therapy. Therapist costs were estimated with the use of VA data for 1-hour sessions, with 15 minutes of contact between the therapist and the patient for the robot-assisted therapy and 60 minutes for the intensive comparison therapy. We tracked patients' use of health care services and their costs using national VA databases. Patients reported any use of non-VA services or caregivers. Costs were standardized to 2008 dollars with the use of the general consumer price index. We analyzed costs, along with log-transformed costs.
Statistical Analysis
The trial was designed to test the superiority of robot-assisted therapy, as compared with intensive comparison therapy or usual care, with the use of a one-sided type I error of 0.025; however, two-sided P values are reported. The significance level was set at 0.022 (two-sided P value) to adjust for the two treatment comparisons and interim monitoring for the treatment effect. [11] [12] [13] [14] [15] [16] The distributions of baseline characteristics were compared in the three groups by analysis-of-variance or chi-square tests, as appropriate, with a significance level of 0.05. Calculation of the sample size was based on the ability to detect a mean difference of 5 points in the Fugl-Meyer score between robot-assisted therapy and usual care and 3 points between robot-assisted therapy and intensive comparison therapy, on the assumption that the study would have a common standard deviation of 5 points, a loss-to-follow-up rate of 10%, and a power of 90%. The target sample size was 158 patients, with 26 assigned to usual care and 66 each to robot-assisted therapy and intensive comparison therapy. The rationale for selecting the effect sizes was based on a 3-point change in the Fugl-Meyer score, which represented a change that was clinically meaningful and of sufficient magnitude to differentiate patients on the basis of their disability score on the Modified Rankin Scale. 4 Because robot-assisted therapy was hypothesized to be much more effective than usual care, a 5-point difference was considered meaningful for this comparison.
We used sample variance to perform interim monitoring of maximum information for each study group for possible sample-size readjustment; treatment differences were monitored for efficacy and futility with the use of an information-based group sequential design with sloped boundaries. [11] [12] [13] [14] [15] [16] All analyses were performed according to randomized treatment assignment. Analysis of co-variance was used to test the effect of treatment on the primary and secondary outcomes at 12 weeks, with adjustment for the study site as a fixed effect, the Comorbidity Disease Index, 17, 18 and the baseline value of the outcome. For patients who missed the 12-week assessment, the next available post-treatment assessment was used, and patients who missed all post-treatment assessments were excluded from the 12-week analysis. Because randomization to usual care was stopped after 15 months as specified by the protocol, comparisons of robot-assisted therapy with usual care included only patients who were recruited during this period; comparisons between robot-assisted therapy and intensive comparison therapy included all patients who underwent randomization and were evaluated.
Secondary analyses used longitudinal methods to assess the effect of treatment on outcomes on the basis of all available data at 6, 12, 24, and 36 weeks. Sensitivity analyses were conducted with the use of multiple imputation to replace missing data. In addition, exploratory analyses were conducted to examine the association between outcomes and the time from the index stroke until study entry. Results are presented as least-squares means with standard errors or 95% confidence limits. All statistical analyses were performed with the use of SAS software, version 9.1.
R e sult s
Study Participation
From November 8, 2006 , to October 31, 2008, we screened 200 patients, of whom 127 underwent randomization: 49 to robot-assisted therapy, 50 to intensive comparison therapy, and 28 to usual care ( Fig. 1) . Enrollment in the usual-care group was stopped after 15 months, when the target information had been attained per protocol. Recruit- with an upper limit of 120 seconds per task. The tasks are averaged to produce a score that ranges from 0 to 120 seconds, with higher scores indicating worse functioning. † † The Stroke Impact Scale is a self-reported measure of quality of life in the domains of hand function, activities or instrumental activities of daily living, mobility, and social participation. Scores range from 0 to 100, with higher scores indicating better functioning and greater social participation. ‡ ‡ The numerical rating scale for pain ranges from 0 to 10, with higher scores indicating worse pain. § § The Modified Ashworth Scale measures spasticity (muscle tone) on a scale of 0 to 5, with higher scores indicating more severe spasticity.
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ment to the robot-assisted and intensive-comparison groups continued until the scheduled end of enrollment at 24 months. The data and safety monitoring board did not recommend extending recruitment for these two treatment groups because the increase in sample size that would be necessary to achieve maximum information (a total of 262 patients) was not feasible, and conditional power to detect a treatment difference for the observed trend was low (2%). The most common reason for exclusion of patients from the study was a baseline Fugl-Meyer score outside the required range of 7 to 38 points (see Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM .org). A total of 111 patients (87%) completed the final study visit. The mean (±SD) number of therapy sessions attended was 33±8 for robot-assisted therapy and 32±8 for intensive comparison therapy, with a median of 36 sessions attended in both groups.
Baseline Characteristics of the Patients
The baseline characteristics of the treatment groups were similar, except for the time from the index stroke to randomization (P = 0.04 for all comparisons) ( Table 1 ). The mean age was 64.6±11.3 years; 96% of the patients were men; 78% were white and 19% were black. The most frequent type of stroke was ischemic (in 85% of the patients). The average time from the index stroke until study entry was 4.7 years (range, 0.5 to 23.6), and 33% of the patients had multiple strokes that were identified on imaging. At baseline, the mean FuglMeyer score was 18.9±9.5, the mean time on the Wolf Motor Function Test was 71.1±33.2 seconds, and the mean Stroke Impact Scale score was 49.4±14.7.
A total of 93 patients (73%) were receiving some form of rehabilitation therapy at baseline, and 30 patients (24%) were receiving therapy that targeted upper-limb function. The number of patients who were receiving nonstudy rehabilitation therapy was generally maintained over the followup period, with 84 patients (66%) receiving some type of rehabilitation therapy at 12 weeks and 86 patients (68%) at 36 weeks. The number of patients who were receiving therapy that targeted upper-limb function decreased slightly over time, with 20 patients (16%) receiving such therapy at 12 weeks and 17 (13%) at 36 weeks. There were no significant differences in the number of patients receiving nonstudy therapy across treatment groups at any time point.
Effectiveness
Primary Outcome
At 12 weeks, the mean Fugl-Meyer score for patients receiving robot-assisted therapy was better than that for patients receiving usual care (difference, 2.17 points; 95% confidence interval [CI], −0.23 to 4.58) and worse than that for patients receiving intensive comparison therapy (difference, −0.14 points; 95% CI, −2.94 to 2.65). However, the between-group differences were not significant ( Table 2) .
Secondary Outcomes
Patients receiving robot-assisted therapy, as compared with those receiving usual care, had significant improvement in motor function and social participation at 12 weeks, as measured on the Stroke Impact Scale, but there was no significant between-group difference in the speed of motor-task performance, as measured on the Wolf Motor Function Test.
The results of longitudinal analyses during the 36-week study period are presented in Figure 2 . Patients receiving robot-assisted therapy had significantly more improvement in Fugl-Meyer scores and Wolf Motor Function Test times during the 36-week study period than did those receiving usual care. Differences between robot-assisted therapy and intensive comparison therapy were not significant. The results were similar when missing values were replaced by multiple imputation (data not shown). A longer interval between the index stroke and enrollment in the study was significantly associated with a worse Fugl-Meyer score at each time point and with worse scores on the Stroke Impact Scale over the 36-week study period. However, when the interval between the index stroke and enrollment was included in the adjusted models, the treatment effects were similar, and the conclusions did not change for any of the outcomes at any of the time points (data not shown).
Safety
There were no treatment-related serious adverse events (Table 3) . Treatment-related adverse events were mild (e.g., transient muscle soreness); 12 patients (24%) receiving robot-assisted therapy and 9 (18%) receiving intensive comparison therapy reported having a nonserious treatment-related event. There were no significant differences in scores on numerical rating scales for pain or spasticity among treatment groups at 12 weeks or over a period of 36 weeks.
Cost Analysis
The average per-patient cost of therapy was $5,152 for patients receiving robot-assisted therapy and $7,382 for those receiving intensive comparison therapy. After 36 weeks, the average total cost (therapy plus the cost of all other health care use) was $17,831 for robot-assisted therapy, $19,746 for intensive comparison therapy, and $19,098 for usual care. The treatment differences were not significant on the basis of non-log-transformed costs, though the costs for the two active-therapy groups were significantly more than the cost for usual care on the basis of log-transformed cost models (P<0.01 for both comparisons).
Discussion
In this study of rehabilitation strategies for patients with moderate-to-severe upper-limb impairment 6 months or more after a stroke, we found no significant benefit of robot-assisted therapy over intensive comparison therapy or usual care. At 12 weeks, there was no significant difference in primary or secondary outcomes, except for the score on the Stroke Impact Scale, which showed significant improvement with robot-assisted therapy, as compared with usual care. In secondary analyses, robot-assisted therapy had a significant but modest effect in improving motor function and motor recovery during the 36-week study period, as compared with usual care; similar improvements in these measures were also observed for intensive comparison therapy. Treatment methods and the duration of treatment appeared to be acceptable to patients, with approximately 90% of therapy sessions completed, on average. Adverse events were mild, and there were no reports of treatment-related serious adverse events. Unlike most previous studies of rehabilitation strategies, which evaluated therapies in patients with less impairment after a single stroke and focused on the acute and subacute periods after the stroke, 19-29 our study used eligibility criteria that were broad, a factor that enhances the generalizability of our findings to an increased population of stroke survivors. As compared with patients in previous studies, our patients had more severe impairment for a longer period of time after their stroke, and approximately one third had had multiple strokes. These factors may have contributed to our finding that robot-assisted therapy at 12 weeks did not provide a benefit with respect to the primary outcome. Rehabilitation studies that have been conducted during the acute stroke phase suggest that a change of 6 to 7 points (or 10%) in the Fugl-Meyer score is clinically meaningful because it advances the patient to the next stage of motor recovery. 30, 31 However, the magnitude of change in the Fugl-Meyer score that is necessary to produce real-world effects for patients during long-term recovery may be smaller, especially for those with severe impairment. The improvements that were detected over a period of 36 weeks in our study provide evidence of potential long-term benefits of rehabilitation and challenge the widely held clinical belief that gains in motor function are not possible for long-term stroke survivors. 30 Moreover, the gains made by patients in the two active-treatment groups that were apparent during the 36-week study period may have occurred as incremental motor improvement was incorporated into the patient's daily routine. There is no universally accepted protocol for upper-limb rehabilitation after stroke, and treatment programs vary in the duration, intensity, and frequency of rehabilitative therapy. A major advantage of this study was that the protocols for active therapy controlled the intensity, duration, and method of movements to improve consistency and reproducibility of training. Both treatment protocols included a large number of sessions (36) and a large number of movements per session (more than 1000 vs. 45 for typical stroke treatment). 32 The modest levels of improvement that were observed in the two active-therapy groups during the 36-week study period suggest that highintensity, repetitive, task-oriented movement training may be necessary for motor recovery. It is not known whether a shorter duration of therapy or fewer movements per session could have a similar effect because the robot-assisted training was delivered in a progression of four modules over the 12-week treatment period.
Limitations of the study include a preponderance of men (98%) and the lack of blinding in study-group assignments. In addition, at baseline, nearly one quarter of the patients were engaged in some form of rehabilitative therapy that targeted upper-limb function, and nearly one fifth reported receiving physical or occupational therapy. This high level of baseline rehabilitation was unexpected and may be partially explained by the self-selection of highly motivated patients or by increased access to rehabilitative services within the VA, as compared with the private sector. The average duration of upper-limb rehabilitation sessions at baseline was 3 hours per week, which was the same amount of time as the active therapies, thereby potentially affecting the power to detect treatment effects. Of note, the average time from the index stroke to randomization was approximately 2 years longer in the usual-care group than in the two active-therapy groups; however, the results were similar when the analyses were adjusted for this difference, and none of the conclusions changed. The proportion of patients who were engaged in rehabilitative therapy was generally maintained over the course of the study, and although there was a slight decrease in the number of patients receiving therapy that targeted upper-limb function over time, there were no significant differences across treatment groups at any time point.
In conclusion, we found that 36 1-hour, highintensity sessions of robot-assisted rehabilitative therapy for stroke survivors who had had moderate-to-severe upper-limb impairment for at least 6 months did not significantly improve motor function, as compared with usual care or intensive comparison therapy, at 12 weeks. However, over the 36-week study period, robot-assisted therapy resulted in significant but modest improvements in motor capability and motor-task performance, as compared with usual care but not with intensive comparison therapy. The study provides evidence of the potential long-term benefits of intensive rehabilitation in patients with moderateto-severe impairment even years after a stroke.
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